GlassScriptPhysician profile
Devin Dhiren Mehta
NPI 1922361344
$26,295.50
in general payments reported to CMS, 2019-2025
27 companies · $5,367 in 2025
The $5,367 reported for 2025 was more than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,666 · 2020: $1,336 · 2021: $7,668 · 2022: $7,480 · 2023: $888 · 2024: $891 · 2025: $5,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,023 · Food and Beverage: $3,064 · Travel and Lodging: $38.88 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,023.00 |
| Food and Beverage | $3,063.74 |
| Travel and Lodging | $38.88 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $11,060.80 | 2019-2025 | |
| Abbott Laboratories | $7,906.58 | 2019-2025 | Cardiomems, Thoratec Heartmate 3 Lvas Implant Kit, Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $4,333.80 | 2025 | |
| Novartis Pharmaceuticals Corporation | $1,212.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $233.69 | 2022-2024 | Verquvo, Steglatro, Belsomra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $194.97 | 2019-2023 | Lifevest |
| Amgen INC. | $148.88 | 2023-2025 | Repatha, Repatha |
| Abiomed | $135.92 | 2019-2025 | Impella |
| Medtronic Vascular, INC. | $135.38 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.85 | 2022-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $112.49 | 2021-2025 | Camzyos, Eliquis |
| Astrazeneca Pharmaceuticals LP | $108.69 | 2019-2025 | Wainua, Lokelma, Farxiga |
| United Therapeutics Corporation | $95.81 | 2019 | |
| Janssen Pharmaceuticals, INC | $88.85 | 2019-2023 | Xarelto |
| Cvrx, INC. | $65.22 | 2022-2025 | Barostim Neo System |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kestra Medical Technology Services, INC. | $45.79 | 2024 | Assure Wcd |
| Lexicon Pharmaceuticals, INC. | $42.67 | 2023 | Inpefa |
| Novo Nordisk INC | $41.94 | 2023 | Rybelsus, Ozempic |
| Impulse Dynamics (USA) INC. | $32.12 | 2023 | Optimizer |
| Philips North America LLC | $29.27 | 2022 | |
| Inari Medical, INC. | $26.81 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Regeneron Healthcare Solutions, INC. | $26.08 | 2019 | |
| Medtronic, INC. | $23.75 | 2025 | Symplicity G3 |
| Cardiva Medical, INC. | $18.13 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Nuwellis, INC. | $17.08 | 2019 | |
| Livanova USA, INC. | $16.83 | 2021 | |
| Terumo Medical Corporation | $14.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Devin Mehta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.